Navigation Links
Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
Date:3/18/2009

TSX Venture: QPT

EDMONTON, March 18 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced that it has formed a strategic alliance with IntelligentNano Inc. and, as a result of the alliance, the two groups have created a water soluble nano-formulation of Quest's SL052 technology, which has the potential to address a wider range of clinical needs than Quest's current formulation of SL052.

"We have successfully used nanoparticles to make SL052 water soluble while maintaining the biological activity of the drug, whether activated by light or ultrasound," said Dr. Jie Chen, Chief Technology Officer for IntelligentNano, a spin-off company from the Canadian National Research Council's National Institute for Nanotechnology.

"The fulfillment of a second tier of targetable, water-soluble nano-formulations of the SonoLight compounds represents major progress in the adaptation of Hypocrellin-based photodynamic and sonodynamic therapy to a wide spectrum of clinical needs including cancer treatment," stated Dr. Madi R. Madiyalakan, Chief Executive Officer at Quest.

The alliance between Quest and IntelligentNano was forged to explore the potential of nanotechnology to provide a multiplicity of biocompatible drug delivery systems for clinical applications of Quest's proprietary SonoLight technology platform. Current SonoLight photosensitizer and sonosensitizer formulations are based upon liposomal drug delivery systems which target the drug to the desired sites of photodynamic or sonodynamic therapies. Quest intends to initiate a series of preclinical studies with these new formulations and arrive at a clinical plan for Quest's second cancer indication.

The results from the product development initiative will be presented at the prestigious Institute of El
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... Research and Markets has announced the addition ... In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to ... The global companion diagnostics market is expected to grow ... Factors such as rising need for personalized medicine in ... pharmaceutical industry, support from regulatory authorities, and emerging technologies ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today that it ... exchange for 6,634 shares of CTI,s Series A, B ... interest of all,series of CTI,s Convertible Preferred Stock. Each ... 7,143 shares of CTI,s common stock, at a,conversion price ...
... $65.0 MillionRICHMOND, Calif., Feb. 4 Sangamo BioSciences, Inc. (Nasdaq: ... year 2008 financial results and accomplishments and provided an outlook ... Sangamo reported a consolidated net loss of $2.6 million, or ... million, or $0.17 per share, for the same period in ...
... Specialty Pharmacy is,pleased to announce two new "Navigator" ... DSP launched both a Hemophilia and IVIG,Navigator Program. ... as National,Sales Manager for both programs. Reed is ... over 18 years of pharmaceutical sales experience. Most ...
Cached Biology Technology:Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 10Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study ... control leg movements with a National Science Foundation ... four-year project. , Ari Berkowitz, professor in the ... Sciences, will focus on the differences between the ... understand what neurotransmitters they use and what connections ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... brain that controls insulin responses has been shown to ... evidence that the disease can be treated in its ... Rhode Island Hospital and Brown Medical School. , ... prevent several components of neurodegeneration and preserve learning and ...
... known that animals use song as a way of attracting ... unusual way of scaring off predators ?by singing to them. ... that wild gibbons in Thailand have developed a unique song ... survival, the gibbons appear to use the song not just ...
... 21 September, 2006 - Elsevier is delighted to ... the journal Vaccine: HPV Vaccines and Screening in ... provides a comprehensive and invaluable update for paediatricians, ... major donor institutions worldwide. , With the arrival ...
Cached Biology News:Insulin receptor stops progression of Alzheimer's disease 2Insulin receptor stops progression of Alzheimer's disease 3Singing for survival 2Singing for survival 3
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... and 2.0 mL samples for freezing point determinations. Includes built-in printer, keypad, ... with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
Biology Products: